Drug Trial Radar · NCT07211425
A Study in Healthy People to Test How Itraconazole Influences the Amount of BI 3031185 in the Blood
Last checked: Nov 20, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Oct 8, 2025
Primary completion
Jan 21, 2026
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this trial is to investigate the effect of multiple oral doses of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics of a single dose of BI 3031185 following oral administration.
Conditions
- Healthy
Interventions
BI 3031185Drug
BI 3031185
ItraconazoleDrug
Itraconazole
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve of BI 3031185 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to Day 13
- Maximum measured concentration of BI 3031185 in plasma (Cmax)Time frame: Up to Day 13
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Humanpharmakologisches Zentrum Biberach
Biberach, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.